Trial · NCT03493451
Results by group98
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 98
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Overall Response Rate (ORR) | Cohort 1: ENKTL | 31.8 | 95% Confidence Interval 13.9 to 54.9 | Percentage of participants | |
| Overall Response Rate (ORR) | Cohort 2: PTCL-NOS, AITL, and ALCL | 20.5 | 95% Confidence Interval 9.8 to 35.3 | Percentage of participants | |
| Overall Response Rate (ORR) | Cohort 3: MF and SS | 45.5 | 95% Confidence Interval 16.7 to 76.6 | Percentage of participants | |
| Duration of Response (DOR) | Cohort 1: ENKTL | NA | 95% Confidence Interval 2.66 to NA | Months | |
| Duration of Response (DOR) | Cohort 2: PTCL-NOS, AITL, and ALCL | 8.2 | 95% Confidence Interval 2.50 to NA | Months | |
| Duration of Response (DOR) | Cohort 3: MF and SS | 11.3 | 95% Confidence Interval 2.76 to 11.30 | Months | |
| Progression-free Survival (PFS) | Cohort 1: ENKTL | 2.7 | 95% Confidence Interval 1.45 to 5.32 | Months | |
| Progression-free Survival (PFS) | Cohort 2: PTCL-NOS, AITL, and ALCL | 2.7 | 95% Confidence Interval 2.56 to 4.76 | Months | |
| Progression-free Survival (PFS) | Cohort 3: MF and SS | 16.8 | 95% Confidence Interval 2.60 to 16.82 | Months | |
| Overall Survival (OS) | Cohort 1: ENKTL | 8.8 | 95% Confidence Interval 3.25 to NA | Months | |
| Overall Survival (OS) | Cohort 2: PTCL-NOS, AITL, and ALCL | 13.3 | 95% Confidence Interval 7.66 to 26.22 | Months | |
| Complete Response Rate (CRR) | Cohort 1: ENKTL | 18.2 | 95% Confidence Interval 5.2 to 40.3 | Percentage of participants | |
| Complete Response Rate (CRR) | Cohort 2: PTCL-NOS, AITL, and ALCL | 9.1 | 95% Confidence Interval 2.5 to 21.7 | Percentage of participants | |
| Complete Response Rate (CRR) | Cohort 3: MF and SS | 9.1 | 95% Confidence Interval 0.2 to 41.3 | Percentage of participants | |
| Time to Response (TTR) | Cohort 1: ENKTL | 5.75 | Full Range 2.1 to 13.9 | Months | |
| Time to Response (TTR) | Cohort 2: PTCL-NOS, AITL, and ALCL | 2.86 | Full Range 2.1 to 5.5 | Months | |
| Time to Response (TTR) | Cohort 3: MF and SS | 6.83 | Full Range 2.6 to 11.1 | Months | |
| Quality of Life Assessment: EQ-5D-5L Change From Baseline in Visual Analogue Score | Cohort 1: ENKTL | Cycle 5, Day 1 | 4.42 | Standard Deviation 10.273 | Score on a scale |
| Quality of Life Assessment: EQ-5D-5L Change From Baseline in Visual Analogue Score | Cohort 2: PTCL-NOS, AITL, and ALCL | Cycle 5, Day 1 | 1.11 | Standard Deviation 13.884 | Score on a scale |
| Quality of Life Assessment: EQ-5D-5L Change From Baseline in Visual Analogue Score | Cohort 3: MF and SS | Cycle 5, Day 1 | 0.25 | Standard Deviation 22.276 | Score on a scale |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03493451/results